Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer

Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer

The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

Further informations will be provided by Centre Oscar Lambret.

Inclusion Criteria:

• Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
• Treated by exclusive concomitant radiochemotherapy
• Written informed consent

Exclusion Criteria:

• Presence of a second uncontrolled cancer
• Metastatic carcinoma
• Metastatic disease, except cervical lymphnodes... (M1a)
• In situ carcinoma
• Eso-gastric junction cancer (Siewert II ou III)
• Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)